March 13 (Reuters) - Mallinckrodt and Endo ( NDOI )
, drugmakers with a shared history of facing U.S.
opioid litigation, have agreed to merge in a deal valued at
nearly $7 billion, the companies said on Thursday.
(Reporting by Sneha S K and Sriparna Roy in Bengaluru; Editing
by Devika Syamnath)